Navigation Links
Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
Date:10/24/2007

SAN MATEO, Calif., Oct. 24 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately-held biopharmaceutical company, reported results of a Phase II clinical trial of its first compound, A-002, for the treatment of cardiovascular disease. The trial results suggest that treatment with A-002 resulted in significant reductions in blood levels of total cholesterol, Non- High Density Lipoprotein Cholesterol (non HDL-C), and Low Density Lipoprotein Cholesterol (LDL-C), known as "bad" cholesterol, coupled with equally meaningful reductions of C-Reactive Protein (CRP), a recognized marker of inflammation and cardiovascular risk. Decreases in these levels with A-002 treatment were most significant among patients already on a background of statin therapy.

The Phase II PLASMA trial (Phospholipase Levels And Serological Markers of Atherosclerosis) was a multi-center, randomized, double-blind, placebo- controlled trial that enrolled approximately 400 patients with stable coronary heart disease in the U.S. and Ukraine. Subjects were randomized to receive one of four different doses of A-002 or placebo for up to eight weeks. Patients also received doctor-determined standard of care therapies. The primary endpoint, a reduction in secretory phospholipase A2 (sPLA2) levels was achieved with a high degree of statistical significance. In addition, the results also demonstrated clinically meaningful as well as statistically significant decreases in cholesterol levels (LDL-C, non-HDL and total cholesterol) in patients with stable coronary heart disease. Clinically meaningful decreases in inflammation, as measured by levels of CRP, were also observed in the relevant patient population. Full data will be presented in a scientific journal during 2008.

"The results of the PLASMA trial support our belief that A-002's unique mechanism of action has a dual effect on lipids and inflammation, which could provide significant therapeutic benefit to patients currently on backgroun
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... BURLINGTON, Mass. , Sept. 22, 2014 Decision ... Chilean pharmaceutical market is expected to be worth $2 billion ... 11.3 percent over the next five years (to 2018). This ... growth of 4.8 percent in 2013 and 4.9 percent expected ... pharmaceutical landscape is small but highly competitive. The ...
(Date:9/22/2014)... 22, 2014 Research and Markets ... "Global Ablation Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, ... to their offering. On the ... technologies market has been divided into eight major ... hydrothermal, and hydromechanical ablation technologies. The light/laser ablation ...
(Date:9/22/2014)... 22, 2014  For many people experiencing issues ... facing the prospect of large, painful incisions and ... activities are also impacted, such as working, driving ... the problem, some patients even delay necessary treatment, ... lead to permanent damage for some conditions. ...
Breaking Medicine Technology:Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 2Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 3Global Ablation Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market - Forecasts to 2019 2Global Ablation Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market - Forecasts to 2019 3Phoenix Arizona Hand Doctor Develops Revolutionary New Surgery System, Eliminates Need for Large Incisions 2
(Date:9/23/2014)... Cubit Labs is pleased to announce ... Play Store. , The popular cross platform contact sharing ... this year, gleaning a solid 5 star rating in ... has never been so easy and I highly recommend ... steps." - CrackBerry.com, View full App review here: ...
(Date:9/23/2014)... PA (PRWEB) September 23, 2014 Rinovum ... home-use conception assistance device on the market cleared by ... in stores and online at http://www.storkotc.com . , ... dream of having a baby is delayed by infertility1 ... first step to optimize their chances to conceive. ...
(Date:9/23/2014)... by researchers from the University of Cambridge has found that ... childhood leaves a ,signature, in the brain. The results ... Cortex . , The researchers studied 80 adult men ... who did not. They found that language delay was associated ... regions, including the temporal lobe, insula, ventral basal ganglia, which ...
(Date:9/23/2014)... 2014 Névo takes a bold step ... and adding advanced activity tracking and phone notifications for ... distance, calories burned, and more. , http://www.nevowatch.com ... healthy habits in their busy lives to look and ... that produce healthy results, but until now, style played ...
(Date:9/23/2014)... Medicine in Motion (MIM) is proud to ... 711 W. 38th, Suite G4. After serving the area’s sports ... increased demand for MIM’s superior care led to the need ... extremely excited about bringing our high-quality brand of sports medicine ... in Motion. “We’ll continue to provide patients with the same ...
Breaking Medicine News(10 mins):Health News:YOUnify for Android is Now Available in the Google Play Store 2Health News:First-Ever Conception Assistance Device FDA-Cleared for Home Use Launches U.S. OTC Sales -- The Stork® OTC Delivers Hope to Millions Struggling to Conceive A Child 2Health News:First-Ever Conception Assistance Device FDA-Cleared for Home Use Launches U.S. OTC Sales -- The Stork® OTC Delivers Hope to Millions Struggling to Conceive A Child 3Health News:First-Ever Conception Assistance Device FDA-Cleared for Home Use Launches U.S. OTC Sales -- The Stork® OTC Delivers Hope to Millions Struggling to Conceive A Child 4Health News:Presence or absence of early language delay alters anatomy of the brain in autism 2Health News:Nevo changes the face of fitness wearables with an analogue watch combining activity tracking, phone notifications, and LED goal progress indicators for active lifestyles 2Health News:Nevo changes the face of fitness wearables with an analogue watch combining activity tracking, phone notifications, and LED goal progress indicators for active lifestyles 3Health News:Austin Sports Medicine Practice to Host Grand Opening Event for Second Location 2
... Creates New Opportunities for Expansion of HIFU Technology, ... (USHIFU), the,distributor and provider of non-invasive high intensity ... has completed the acquisition,of Focus Surgery, Inc. (FSI) ... Sonablate(R) 500, an image-guided acoustic ablation,device. This acquisition ...
... of today,s,announcement that Attorney General Mike Cox is filing ... Coalition for a Fair and,Competitive Insurance Market is calling ... Cross Blue Shield of Michigan (BCBSM) to use their,unfair ... insurance., "We were confident when we raised this ...
... 2 A Miami resident was,sentenced to 130 months ... the,Medicare program, Acting Assistant Attorney General Matthew Friedrich of,the ... the Southern,District of Florida announced today., Gustavo Smith, ... for,the Southern District of Florida by Judge Marcia G. ...
... could one day help tailor treatments to individual patients, study ... technique for finding and analyzing stray cancer cells in the ... doctors to one day not only determine the genetic "signature" ... and adjust treatments accordingly. , "I think this is ...
... QC, July 2 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: ... a complete response to,the Food and Drug Administration ... the FDA,s Deputy Director, Center for Drug Evaluation,and ... regulatory path towards,potential U.S. approval of the Company,s ...
... July 2, 2008 -- Compact, bedside brain-activity monitors ... Washington University School of Medicine in St. Louis ... clinicians in monitoring for electrical seizures until confirmation ... an article published in the June issue of ...
Cached Medicine News:Health News:USHIFU, LLC Completes Acquisition of Focus Surgery, Inc. 2Health News:Coalition Calls on MI Legislature to Abandon Blue Cross Legislation 2Health News:Owner of Medical Equipment Company Sentenced to 130 Months in Prison for Health Care Fraud 2Health News:Owner of Medical Equipment Company Sentenced to 130 Months in Prison for Health Care Fraud 3Health News:Circulating Tumor Cells Reveal Insights Into Lung Cancers 2Health News:Circulating Tumor Cells Reveal Insights Into Lung Cancers 3Health News:Labopharm Submits Complete Response to FDA as a Result of Outcome of Appeal Process for Once-Daily Tramadol 2Health News:Seizures in newborns can be detected with small, portable brain activity monitors 2Health News:Seizures in newborns can be detected with small, portable brain activity monitors 3
Li Brand™ Surgical Hemostat. ("dissecting clamp") For NSV and other procedures....
... The 2201 is ideal for applications ... application of heat. , ,The autoclavable ... assortment of reusable thermal cautery electrodes, ... flexibility to perform a wide variety ...
No Scalpel Vasectomy Hemostat 5 1/2" (14cm), smooth sharp point, curved, gold finger rings...
Li Brand™ Ringed Forceps. ("fixation clamp") For NSV and other procedures. Ring diameter approximately 3.5 mm. Manufactured exclusively for AMI to exacting specifications by a German company....
Medicine Products: